June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
U.S. regulators expand treatment options in prostate cancer as biotech innovators TRexBio and Spinogenix push forward with immune …
A phase 3 study reveals combining inavolisib with fulvestrant and palbociclib substantially delays progression and prolongs survival in …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
